Clinical TrialMay 31, 2026, 07:32 PM
Ascentage Pharma's Olverembatinib Combo Shows Promising Ph Ib Results
AI Summary
Ascentage Pharma announced positive results from a Phase Ib study of olverembatinib in combination with blinatumomab for lymphoid blast phase chronic myeloid leukemia (CML-LBP) or Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia (Ph+ BCP-ALL). The data, presented at the 2026 ASCO Annual Meeting, showed encouraging clinical activity with strong response rates and minimal residual disease (MRD) clearance in international patients. The combination regimen was generally well tolerated, consistent with individual agent toxicities, highlighting its potential as a novel, chemotherapy-free strategy.
Key Highlights
- Ascentage Pharma presented positive Phase Ib study results for olverembatinib combined with blinatumomab at ASCO 2026.
- The combination showed encouraging clinical activity in relapsed/refractory Ph+ BCP-ALL or CML-LBP patients.
- 91% (10/11) of patients achieved complete response (CR) or complete response with incomplete hematologic recovery (CRi).
- 67% (8/12) of patients achieved BCR::ABL1 negativity by PCR (≤0.01%).
- 80% (8/10) of patients achieved minimal residual disease (MRD) negativity by flow cytometry (≤0.01%).
- The combination regimen was generally well tolerated, with a safety profile consistent with individual agents.
- Olverembatinib is approved in China for TKI-resistant CML-CP/AP with T315I mutation and TKI-resistant CML-CP.
- Ascentage Pharma is conducting three global registrational Phase III studies for olverembatinib.
Price Impact
More from AAPG